Shares of Xenon Pharmaceuticals Inc (NASDAQ:XENE) have earned a consensus recommendation of “Buy” from the seven research firms that are covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $22.00.
XENE has been the subject of several analyst reports. Wedbush began coverage on Xenon Pharmaceuticals in a report on Tuesday. They issued an “outperform” rating and a $23.00 price target for the company. William Blair assumed coverage on Xenon Pharmaceuticals in a report on Wednesday, January 8th. They issued an “outperform” rating for the company. Zacks Investment Research cut shares of Xenon Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, March 14th. BidaskClub cut shares of Xenon Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, March 20th. Finally, ValuEngine raised shares of Xenon Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, March 9th.
A number of large investors have recently bought and sold shares of XENE. BVF Inc. IL lifted its position in shares of Xenon Pharmaceuticals by 11.9% during the fourth quarter. BVF Inc. IL now owns 1,949,075 shares of the biopharmaceutical company’s stock worth $25,552,000 after purchasing an additional 207,475 shares during the last quarter. Cubist Systematic Strategies LLC lifted its position in shares of Xenon Pharmaceuticals by 1,452.0% during the fourth quarter. Cubist Systematic Strategies LLC now owns 25,515 shares of the biopharmaceutical company’s stock worth $335,000 after purchasing an additional 23,871 shares during the last quarter. Schonfeld Strategic Advisors LLC bought a new position in shares of Xenon Pharmaceuticals during the fourth quarter worth about $910,000. Bank of America Corp DE bought a new position in shares of Xenon Pharmaceuticals during the fourth quarter worth about $34,000. Finally, Marshall Wace LLP bought a new position in shares of Xenon Pharmaceuticals during the fourth quarter worth about $637,000. 56.04% of the stock is owned by institutional investors.
XENE stock traded up $0.20 on Monday, reaching $11.45. The company had a trading volume of 1,810 shares, compared to its average volume of 288,364. Xenon Pharmaceuticals has a 1 year low of $7.00 and a 1 year high of $18.45. The company has a debt-to-equity ratio of 0.13, a quick ratio of 3.34 and a current ratio of 3.34. The company’s fifty day moving average is $13.96 and its 200 day moving average is $12.11. The company has a market cap of $389.76 million, a P/E ratio of -7.31 and a beta of 1.36.
Xenon Pharmaceuticals (NASDAQ:XENE) last posted its earnings results on Monday, March 9th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.54). The company had revenue of $3.33 million during the quarter, compared to analysts’ expectations of $25.00 million. On average, sell-side analysts predict that Xenon Pharmaceuticals will post -1.36 earnings per share for the current year.
Xenon Pharmaceuticals Company Profile
Xenon Pharmaceuticals, Inc engages in discovering and developing therapeutics to improve the lives of patients with neurological disorders. It focuses on the treatment of epilepsy. Its products include XEN496, XEN1101, XEN901, and XEN007. The company was founded by Simon Neil Pimstone, Johannes J. P.
Featured Article: Trade War
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.